Biotech Ideas

[gfp927z]

Oct 2021 - >>> Jasper Therapeutics soars on Oppenheimer outperform initiation


Oct. 13, 2021

Seeking Alpha

By: Jonathan Block


https://seekingalpha.com/news/3752389-jasper-therapeutics-soars-on-oppenheimer-outperform-rating?gclid=EAIaIQobChMIheSvzpjg9QIV4BXUAR3apQEPEAMYASAAEgKdFPD_BwE&utm_campaign=14049528666&utm_medium=cpc&utm_source=google&utm_term=137460309828%5Edsa-1455881688143%5E%5E555764444353%5E%5E%5Eg


Jasper Therapeutics (NASDAQ:JSPR) is the best performing biotech stock of the day after Oppenheimer initiated shares with an outperform rating.

The firm noted the company is positioned to disrupt the hematopoietic stem cell transplantation market.

"We view JSPR as well-positioned to potentially transform the decades-old standard HSCT for various diseases either as a standalone conditioning agent or as the backbone of the conditioning regimen," analyst Jay Olsen says.

Its lead candidate, JSP191 is currently in development for severe combined immunodeficiency, myelodysplastic syndromes, and acute myeloid leukemia.

Jasper went public late last month through a SPAC merger with Amplitude Healthcare Acquisition Corporation.

<<<